$SKK expands its global reach with a new contract with IBM. Key highlights: - Commences Oct 2026 with immediate revenue contribution - Volume revenue expected to boost FY27 targets - Extends momentum following Candescent & FBI wins Doing all right moves to be multi bagger

$XRO is down on the negative sentiment of AI and SaaS beating. At current prices $XRO has more than 100% gain potential based on revenue and steady growth. AI should help the company to make better margin rather than downgrade in revenue. I am accumulating on each dip.

$SKK has gone live with the FBI, delivering AI-powered signature verification to combat fraud. With Phase 1 live and Phase 2 underway, the contract runs through Dec 2027 and pushes FY27 revenue targets above $55M! #ASX #FinTech #CyberSecurity #AI

Stakk (ASX: $SKK) completes US$63M acquisition of ParaScript, launching a global AI-native Digital Trust platform! Targeting A55.2M revenue & A18.5M EBITDA in FY27 across 110B+ annual interactions. Well positioned for growth. #Fintech #AIFraud #ASX $SKK

$TLX has secured U.S. FDA approval for Pixclara making it the first and only FDA-approved PET imaging drug for glioma (brain cancer). Indicated for adult and pediatric patients (1 month+). Great long process with approval opening new revenue opportunities.

$BIO Biome has signed an exclusive 3-year deal with H&S Global for cross-border e-commerce distribution in China (targeting FY27). The move targets a US$10.8B market with zero CapEx or local registration needed, leveraging its position as Australia's #1 pharmacy probiotic brand.

$BOE Boss Uranium $2.5M NPAT in FY26 (up from a -$34.2M loss in FY25) as revenue doubles to $151.1M at $111/lb realized U_3O_8. With $207.3M cash, zero debt, and 1.58M lbs in inventory, the turnaround at Honeymoon is officially underway. Holding

$PDN Paladin delivered strong FY2026 growth as the Langer Heinrich Mine ramp-up lifted production 60% to 4.82 Mlb and revenue 71% to US304.3M. Operating cost discipline restored gross profitability to US52.2M and built a US233.0M net cash position. Good recovery. Holding .

$TLX, officially turning profitable with a US$38M Net Profit—a massive US41M swing YoY from a prior net loss. Adjusted EBITDA surged 146% . With cash reserves expanding 78% to US252M and a US$40M . On track for the upper end of its FY 2026 guidance.

$TLX a good turnaround update today. Q2 2026 Highlights • Revenue: US$247M (+21% YoY) • FY26 outlook: On track for >$1B total income • Regeneron deal: $40M upfront payment • FDA progress: ProstACT Ph3 advances; Pixclara PDUFA Sep Can mice towards $30 target price

$BIO reported record FY26 revenue of $23.9m, up 30%. Growth was led by a 39% surge in same-store sales, with June units topping 100,000 to make. Backed by onshore manufacturing and expanding footprints in Canada, UK, Ireland, and NZ, is on track for its $75m Vision 27 target.

$TLX good report today . Ticking all stars with 50% revenue increase

$BIO: delivered its best quarterly result ever, achieving $6.5m in revenue (up 41%) and eighth consecutive quarter of positive EBITDA. Biome is financially self-sustaining, generating $1.24m in operating cash flow simultaneously increasing its cash reserves & paying down debt.

$TLX : Telix's strategic partner in China has received approval from the Chinese NMPA for its new drug application for Illuccix, a prostate cancer imaging product. This marks a significant milestone and hopefully will open immense market potential this year.

$SHG has received FDA 510(k) clearance for its 3DICOM MD Cloud, a Class II medical software to expand U.S. commercial strategy. This will improve accessibility by removing hardware barriers and adding support for X-ray and ultrasound, targeting a US$16.5B market opportunity.

$BOT volume coming back